PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CEO Sells $61,915.66 in Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) CEO David Henry Mack sold 58,411 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total value of $61,915.66. Following the transaction, the chief executive officer owned 536,133 shares in the company, valued at approximately $568,300.98. This represents a 9.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

PMV Pharmaceuticals Price Performance

NASDAQ PMVP traded up $0.11 during mid-day trading on Friday, reaching $1.21. The stock had a trading volume of 582,828 shares, compared to its average volume of 197,220. PMV Pharmaceuticals, Inc. has a 1 year low of $0.81 and a 1 year high of $1.82. The stock has a market cap of $62.86 million, a PE ratio of -1.03 and a beta of 1.49. The company has a fifty day moving average price of $0.99 and a 200 day moving average price of $1.18.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.03. As a group, equities research analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current year.

Institutional Investors Weigh In On PMV Pharmaceuticals

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in shares of PMV Pharmaceuticals by 2,282.8% during the 4th quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company's stock valued at $37,000 after acquiring an additional 23,559 shares during the period. Velan Capital Investment Management LP bought a new position in PMV Pharmaceuticals in the 4th quarter worth approximately $53,000. Squarepoint Ops LLC boosted its stake in PMV Pharmaceuticals by 68.7% in the 4th quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock worth $110,000 after purchasing an additional 29,722 shares during the period. Northern Trust Corp boosted its stake in PMV Pharmaceuticals by 23.2% in the 4th quarter. Northern Trust Corp now owns 107,340 shares of the company's stock worth $162,000 after purchasing an additional 20,190 shares during the period. Finally, Bridgeway Capital Management LLC boosted its stake in PMV Pharmaceuticals by 44.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company's stock worth $305,000 after purchasing an additional 62,200 shares during the period. 90.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of PMV Pharmaceuticals in a research report on Thursday, March 20th.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.